Leaflet: information for the user
Carvedilol Cinfamed 6.25mg tablets EFG
Read this leaflet carefully before you start taking this medicine, because it contains important information for you.
1. What isCarvedilol Cinfamedand what it is used for
2. What you need to know before starting totakeCarvedilol Cinfamed
3. How to takeCarvedilol Cinfamed
4. Possible side effects
5. Storage ofCarvedilol Cinfamed
6. Contents of the pack and additional information
This medication contains carvedilol as the active ingredient, which belongs to a group of medications known asalpha and beta receptor blockers. Carvedilol has antioxidant properties, antihypertensive (blood pressure reduction), vasodilatory, and antianginal properties. It also reduces cardiac output, and has favorable effects on blood circulation at the heart level.
This medication is indicated for the treatment of:
Do not take Carvedilol Cinfamed:
Warnings and precautions
Consult your doctor or pharmacist before starting to take this medication.
Inform your doctorif you have any of the following diseases:
As with all beta-blocker medications, do not stop treatment abruptly. The dose should be gradually reduced according to your doctor's instructions.
Use in athletes
This medication contains carvedilol, which may produce a positive result in doping control tests.
Carvedilol Cinfamed with other medications
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication.
This isvery important, as taking multiple medications at the same time may increase or decrease their effect.
Do not take this medication with any other medication unless your doctor has allowed it.
Be aware that these instructions may also apply to medications that have been used before or may be used later.
It is essential to inform your doctor if you are taking or have taken recently any of the following medications:
-Fluoxetine and Paroxetine (depression medications).
-Ciclosporin (medication used to prevent transplant rejection).
-Digoxin, Verapamil, Diltiazem, and anti-arrhythmic medications (medications used to treat heart problems and high blood pressure).
-Amiodarone (medication used to treat certain heart problems).
-Certain analgesics of the type of Aspirin and Ibuprofen(NSAIDs).
-Other blood pressure medications, barbiturates, phenothiazines, tricyclic antidepressants, vasodilators, and alcohol.
-Diabetes medications (including insulin and oral antidiabetic medications).
-Clonidine (medication used to control high blood pressure or migraines).
-Rifampicin, (medication to treat infections).
-Cimetidine (medication to treat gastrointestinal problems).
-Inducers or inhibitors of hepatic metabolism (medications that modify the elimination of other medications from the body).
-MAO inhibitors (medications for depression).
-Beta-agonist bronchodilators (medications used to improve respiratory function, such as in asthma).
Carvedilol Cinfamed with food and drinks
Avoid taking alcohol during treatment with this medication, as it may modify its effects.
Your doctoror pharmacistwill inform you aboutthe meals with which it is recommended to take themedication.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or if you think you may be pregnant, consult your doctor before using this medication.
This medication is not recommended during pregnancy and breastfeeding.
Carvedilol may cause fetal death in the womb, as well as premature birth. Additionally, adverse effects may occur in the fetus and newborn. After birth, the newborn has a higher risk of heart and lung problems.
Carvedilol passes into breast milk, so it is not recommended to use it during breastfeeding.
Driving and operating machinery
In some cases, this medication may impair your ability to drive or operate machinery. This occurs especially when starting or changing treatment and when taken with alcohol.
Carvedilol Cinfamed contains lactose
If your doctor has told you that you have a lactose intolerance, consult with them before taking this medication.
Follow exactly the administration instructions of this medication indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Essential hypertension:
Adults:
Oral route. The recommended starting dose is 12.5 mg once a day for the first two days. Subsequently, the recommended dose is 25 mg once a day. If necessary, your doctor may increase the dose you receive (at intervals of at least two weeks) to 50 mg once a day or in two doses of 25 mg each.
Older patients:
Oral route. The recommended starting dose is 12.5 mg once a day, which is usually sufficient. If the response is not adequate, your doctor will adjust the dose (at intervals of at least two weeks).
Ischemic cardiopathy:
Adults:
Oral route. The recommended starting dose is 12.5 mg twice a day (total 25 mg per day) for the first two days. Subsequently, the recommended dose is 25 mg twice a day (total 50 mg per day). If necessary, your doctor may increase the dose you receive (at intervals of at least two weeks) to 100 mg once a day or in two doses of 50 mg each.
Older patients:
Oral route. The maximum recommended dose for older patients is 50 mg administered in divided doses (twice a day).
Chronic heart failure symptomatic treatment
Adults and elderly:
Oral route. Your doctor will tell you individually the dose you should take, closely monitoring you during the adjustment to higher doses.
In the case of using heart disease medications (digitalis) or blood pressure control medications (diuretics and/or ACE inhibitors) and before starting treatment with this medication, your doctor will adjust the amount of these types of medications you should take.
In any case, the recommended starting dose for treatment with this medication in the symptomatic treatment of chronic heart failure is 3.12 mg twice a day (total 6.25 mg per day) for two weeks. If you tolerate this dose well, it can be increased subsequently (at intervals of at least two weeks) to 6.25 mg twice a day (total 12.5 mg per day).
Your doctor may prescribe you higher doses of this medication subsequently (at least two weeks after).
If you weigh less than85 kg, the maximum recommended dose is 25 mg twice a day (total 50 mg per day). If your weight is greater than85 kg, the maximum recommended dose is 50 mg twice a day (100 mg per day).
Your doctor will indicate the duration of your treatment with this medication.
As a general rule, regardless of your disease, the withdrawal of this medication should be done gradually over a few days, or reduce the dose by half every three days.
Use in children and adolescents
This medication is not recommended for use in children and adolescents under 18 years due to the lack of sufficient data on safety and efficacy.
Guidelines for correct administration
Take the tablets with a sufficient amount of liquid, a glass of water.
If you have congestive heart failure (your heart has lost a little of its ability to pump blood and may produce difficulty breathing, weakness, and fluid accumulation), you should take this medication while eating, to avoid the feeling of dizziness when standing up.
Remember to take your medication.
If you take more Carvedilol Cinfamed than you should
If you take more Carvedilol Cinfamed than you should, contact your doctor immediately or go to the nearest hospital. Bring the medication with you.
In case of overdose or accidental ingestion, consult the Toxicological Information Service, Telephone 91 562.04.20.
If you forgot to take Carvedilol Cinfamed
Do not take a double dose to compensate for the missed doses.
If you interrupt treatment with Carvedilol CinfamedCinfamed
Treatment with this medication should not be interrupted abruptly, especially if you have ischemic cardiopathy, a disease that causes the heart not to pump blood well. Your doctor will gradually reduce the dose over a few days until you stop taking this medication completely.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Side effects are classified as: very common (can affect more than 1 in 10 people), common (can affect up to 1 in 10 people), uncommon (can affect up to 1 in 100 people), rare (can affect up to 1 in 1,000 people), very rare (can affect up to 1 in 10,000 people) and unknown frequency (cannot be estimated from available data).
Infections and infestations
Common:Bronchitis, pneumonia, upper respiratory tract infections, urinary tract infections
Nervous system disorders
Very common:Headache, dizziness, and weakness that are usually mild and occur mainly at the beginning of treatment.
Common:Presyncope, syncope (fainting), especially at the beginning of treatment.
Uncommon:Paresthesias (tingling sensation).
Mental and behavioural disorders
Common:Depressed mood, depression.
Uncommon: Sleep disorders.
Cardiac disorders
Very common: Worsening of heart failure (the heart has lost some of its ability to pump blood).
Common:Bradycardia (decreased heart rate), fluid overload, increased blood volume in the body.
Uncommon:Atrioventricular block (AV) (heart problems), and angina pectoris (chest pain).
Vascular disorders
Very common: Low blood pressure.
Common:Postural hypotension (dizziness when standing or changing position, peripheral circulation disorders (cold hands and feet), worsening of symptoms in patients with intermittent claudication (increased pain in the legs when walking), Raynaud's phenomenon (decreased blood flow to the fingers and toes, ears, and nose), hypertension.
Respiratory, thoracic and mediastinal disorders
Common:Asthma and breathing difficulties in predisposed patients, accumulation of fluid in the lungs.
Rare:Nasal congestion.
Gastrointestinal disorders
Common:Gastrointestinal discomfort with symptoms such as nausea, diarrhea, and abdominal pain, indigestion, vomiting.
Uncommon:Constipation.
Rare:Dry mouth.
Skin and subcutaneous tissue disorders
Uncommon:Cutaneous reactions (e.g. allergic exanthema, dermatitis, urticaria, pruritus, psoriasis, cutaneous lesions of the type lichen planus).
Unknown frequency: Hair loss, severe cutaneous adverse reactions (e.g. toxic epidermal necrolysis, Stevens-Johnson syndrome).
Haematological and lymphatic system disorders
Common:Decreased red blood cell count in blood (anemia).
Rare:Decreased platelet count in blood (thrombocytopenia).
Very rare:Decreased white blood cell count in blood (leucopenia).
Hepatobiliary disorders
Very rare:Alterations in serum transaminases (changes in the amount of certain liver enzymes in the blood).
Ocular disorders
Common:Decreased tear production (dry eye), eye irritation, visual disturbances.
Renal and urinary disorders
Common:Acute renal failure (kidney not functioning well) and renal function disorders in patients with diffuse vascular disease and/or altered renal function.
Rare:Urination problems.
Unknown frequency:Urinary incontinence in women (disappears when stopping treatment).
Immune system disorders
Very rare:Allergic reactions.
Musculoskeletal and connective tissue disorders
Common:Leg pain.
Reproductive and breast disorders
Uncommon:Impotence.
Metabolism and nutrition disorders
Common:Worsening of blood sugar control in patients with diabetes (hyperglycemia, hypoglycemia), weight gain, increased blood cholesterol.
Unknown frequency: It may manifest latent diabetes, or an existing diabetes may worsen.
General disorders and administration site conditions
Very common:Fatigue.
Common:Pain, edema (fluid retention, swelling of the legs, ankles, and feet).
If you consider that any of the side effects you are experiencing is severe or if you notice any side effect not mentioned in this leaflet, inform your doctor or pharmacist.
Reporting of side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect not mentioned in this leaflet. You can also report them directly through theSistema Español de Farmacovigilancia de Medicamentos de Uso Humano:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep out of sight and reach of children.
Do not store at a temperature above30°C. Store in the original packaging to protect it from humidity.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Medicines should not be disposed of through drains or in the trash. Deposit the packaging and unused medicines at the SIGRE collection pointof the pharmacy. If in doubt, ask your pharmacist how to dispose of unused packaging and medicines. By doing so, you will help protect the environment.
Composition of Carvedilol Cinfamed
Appearance of the product and contents of the packaging
Carvedilol Cinfamed tablets are white, oval-shaped, coated tablets with a notch on both sides and marked with “6.25” on one side.
This medication is presented in PVC/Aclar/Al blisters in packaging of 28 or 500 tablets.
Holder of the marketing authorization and responsible for manufacturing
Holder
Cinfa Laboratories, S.A
Olaz-Chipi Road, 10. Areta Industrial Estate
31620 Huarte (Navarra) – Spain
Manufacturing Responsible:
ROVI Pharma Industrial Services, S.A.
Complutense Avenue, 140
Alcalá de Henares
28805 (Madrid)
Spain
Or
Cinfa Laboratories, S.A
Olaz-Chipi Road, 10. Areta Industrial Estate
31620 Huarte (Navarra) – Spain
Last review date of this leaflet:June 2016
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/.
You can access detailed and updated information on this medication by scanning the QR code included in the leaflet and packaging with your smartphone. You can also access this information at the following internet address:
https://cima.aemps.es/cima/dochtml/p/65885/P_65885.html
QR code to:https://cima.aemps.es/cima/dochtml/p/65885/P_65885.html
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.